Literature DB >> 8830056

Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine.

S Tsubuki1, Y Saito, M Tomioka, H Ito, S Kawashima.   

Abstract

To explore membrane-permeable synthetic inhibitors that discriminate between endogenous calpain and proteasome in cells, we examined the inhibition of profiles against calpain and proteasome in vitro and in vivo of peptidyl aldehydes possessing di-leucine and tri-leucine. The tripeptide aldehyde benzyloxycarbonyl-leucyl-leucinal (ZLLLal) strongly inhibited calpain and proteasome activities in vitro. The concentration required for 50% inhibition (IC50) of the casein-degrading activity of calpain was 1.25 microM, and the IC50s for the succinyl-leucyl-leucyl-valyl-tyrosine-4-methylcoumaryl-7-amide (Suc-LLVY-MCA)- and benzyloxycarbonyl-leucyl-leucyl-leucine-4-methylcoumaryl -7-amide (ZLLL-MCA)-degrading activities of proteasome were 850 and 100 nM, respectively. On the other hand, the synthetic dipeptide aldehyde benzyloxycarbonyl-leucyl-leucinal (ZLLal) strongly inhibited the casein degrading activity of calpain (IC50 1.20 microM), but the inhibition of proteasome was weak (IC50S for SucLLVY-MCA- and ZLLL-MCA-degrading activities were 120 and 110 microM, respectively). Thus, while calpain was inhibited by similar concentrations of ZLLal and ZLLLal, the inhibitory potencies of ZLLLal against the ZLLL-MCA- and Suc-LLVY-MCA-degrading activities in proteasome were 1,100 and 140 times stronger than those of ZLLal, respectively. To evaluate the effectiveness of these inhibitors on intracellular proteasome, the induction of neurite outgrowth in PC12 cells caused by proteasome inhibition was examined. ZLLLal and ZLLal initiated neurite outgrowth with optimal concentrations of 20 nM and 10 microM, respectively, again showing a big difference in the effective concentrations for the proteasome inhibition as in vitro. As for the effect on intracellular calpain, the concentration of ZLLLal and ZLLal required for the inhibition of the autolytic activation of calpain in rabbit erythrocytes were 100 and 100 microM or more, respectively. The almost equal inhibitory potencies of ZLLLal and ZLLal were in agreement with the inhibition of calpain in vitro. These differential effects of inhibitors against calpain and proteasome are potentially useful for identifying the functions of calpain and proteasome in cell physiology and pathology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830056     DOI: 10.1093/oxfordjournals.jbchem.a021280

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  89 in total

1.  Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM.

Authors:  Haruko Ideguchi; Atsuhisa Ueda; Masatsugu Tanaka; Jun Yang; Takashi Tsuji; Shigeru Ohno; Eri Hagiwara; Akiko Aoki; Yoshiaki Ishigatsubo
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

2.  Effects of phosphatase and proteasome inhibitors on Borealin phosphorylation and degradation.

Authors:  Dipali Date; Megan R Dreier; Michael T Borton; Michael E Bekier; William R Taylor
Journal:  J Biochem       Date:  2012-02-29       Impact factor: 3.387

3.  Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells.

Authors:  Yuzhe Tang; Ruibao Chen; Yan Huang; Guodong Li; Yiling Huang; Jiepeng Chen; Lili Duan; Bao-Ting Zhu; J Brantley Thrasher; Xu Zhang; Benyi Li
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

4.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 5.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

6.  Control of chronic pain by the ubiquitin proteasome system in the spinal cord.

Authors:  Michael H Ossipov; Igor Bazov; Luis R Gardell; Justin Kowal; Tatiana Yakovleva; Ivan Usynin; Tomas J Ekström; Frank Porreca; Georgy Bakalkin
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

7.  A possible intermediate step during apoptotic execution.

Authors:  Masanori Tomioka; Masasumi Sameshima; Hisako Nakano; Toshikazu Kubo; Kunio Shinohora; Yousuke Seyama; Seiichi Kawashima; Shigenobu Toné
Journal:  Hum Cell       Date:  2002-03       Impact factor: 4.174

8.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

9.  HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK.

Authors:  Qiong Lin; Jian Wang; Chandra Childress; Marius Sudol; David J Carey; Wannian Yang
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

10.  Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.

Authors:  Siwei Zhang; Yawei Shi; Hongwei Jin; Zhenming Liu; Liangren Zhang; Lihe Zhang
Journal:  J Mol Model       Date:  2009-05-14       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.